Takeda Pharmaceutical (4502.T) Earnings

In its last earnings report on January 30, 2025, Takeda Pharmaceutical reported earnings per share (EPS) of $0.10, compared to an estimated EPS of $25.86. The company reported revenue of $1.14T, compared to an estimated revenue of $1.14T.

Takeda Pharmaceutical's current Price-to-Earnings (P/E) ratio is 45.16. The trailing twelve months (TTM) P/E ratio is 34.54. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.

For the fiscal year ending March 31, 2024, Takeda Pharmaceutical reported total revenue of $4.26T and net income of $144.07B. This represents a net profit margin of 0.0337887058.

Takeda Pharmaceutical's earnings yield is 2.21%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.

Takeda Pharmaceutical's return on equity (ROE) is 1.98%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.

Takeda Pharmaceutical's gross profit margin is 66.43%. This indicates that for every dollar of revenue, the company retains $0.66 as gross profit after accounting for the cost of goods sold.